MDGL Jan 2025 240.000 call
| Previous close | 66.20 |
| Open | 66.33 |
| Bid | 70.00 |
| Ask | 76.40 |
| Strike | 240.00 |
| Expiry date | 2025-01-17 |
| Day's range | 66.17 - 67.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 75 |
Investor's Business DailyMadrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
GlobeNewswireMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
Investor's Business DailyMadrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.
